EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease

Nuria Barroso-García iD, José Luis Martín-Varillas iD, Iván Ferraz-Amaro iD, Lara Sánchez-Bilbao iD, Adrián Martín-Gutiérrez iD, Alfredo Adán iD, Inés Hernanz-Rodríguez, Emma Beltrán-Catalán, Miguel Cordero-Coma, David Díaz-Valle iD, Marisa Hernández-Garfella, Lucía Martínez-Costa und 18 weitere

Journal of Clinical Medicine · 04.12.2024 · 13 (23) · 7388

DOI: 10.3390/jcm13237388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.12.2024. Verfasst von Nuria Barroso-García und 29 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Hospital Regional Universitario, Universidad de Málaga (UMA), 29010 Málaga, Spain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Investigación Marqués de Valdecilla.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet’s disease (BD) is one of the most commonly conditions related to CME.

Objectives

To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD.

Methods

Multicenter study of BD-CME patients with no response to glucocorticoids (GCs) and at least one conventional immunosuppressive drug. At baseline, all patients presented CME, defined by OCT > 300 µ. The effectiveness of ADA, IFX and CZP was assessed over a 2-year period from baseline using the following ocular parameters: macular thickness (µm), visual acuity (BCVA), anterior chamber (AC) cells and vitritis. Mixed-effects regression models were applied. Results: a total of 50 patients (75 eyes) were studied (ADA = 25; IFX = 15 and CZP = 10). No significant differences in demographic parameters were found among the three groups. However, individuals in the CZP group had a significantly extended time from diagnosis to treatment onset (72 (36–120) months, p = 0.03) and had received a higher number of biological therapies (1.7 ± 1.1) compared to the ADA and IFX groups. Within the CZP group, ADA and IFX were previously administrated in seven patients. After 2 years of follow-up, a rapid and sustained reduction in macular thickness was noted in all three groups with no significant differences between them. Additionally, enhancements in BCVA, AC cells and vitritis were also observed. No serious adverse events were reported in the CZP group, although one isolated case of bacteremia was documented in the ADA group. ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX.

Conclusions

ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX.

Schlagwörter

Stichwörter der Autor:innen

Behçet diseaseTNF inhibitor monoclonal antibodiesadalimumabcertolizumab pegolcystoid macular edemainfliximabuveitis

Autor:innen und Institutionen

  • Rheumatology, Hospital Regional Universitario, Universidad de Málaga (UMA), 29010 Málaga, Spain.
  • Rheumatology, Hospital de Laredo, Instituto de Investigación Valdecilla (IDIVAL), 39770 Cantabria, Spain.
  • Immunopathology Group, Marqués de Valdecilla University Hospital, Instituto de Investigación Valdecilla (IDIVAL), 39011 Santander, Spain.
  • Rheumatology, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain.
  • Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), 39008 Santander, Spain.
  • Ophthalmology, Hospital Clinic de Barcelona, 08036 Barcelona, Spain.

ORCID-Profile: Nuria Barroso-García, José Luis Martín-Varillas, Iván Ferraz-Amaro, Lara Sánchez-Bilbao, Adrián Martín-Gutiérrez, Alfredo Adán, David Díaz-Valle, Ángel García-Aparicio, Patricia Moya-Alvarado, José Luis Hernández, Ricardo Blanco

Förderung

  • Instituto de Investigación Marqués de Valdecilla

Zitieren

APA

Barroso-García, N., Martín-Varillas, J. L., Ferraz-Amaro, I., Sánchez-Bilbao, L., Martín-Gutiérrez, A., Adán, A., Hernanz-Rodríguez, I., Beltrán-Catalán, E., Cordero-Coma, M., Díaz-Valle, D., Hernández-Garfella, M., Martínez-Costa, L., Díaz-Llopis, M., Herreras, J. M., Maíz-Alonso, O., Torre-Salaberri, I., Atanes-Sandoval, A., Insúa, S., Almodóvar-González, R., …, & Blanco, R. (2024). Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease. Journal of Clinical Medicine, 13(23), 7388. https://doi.org/10.3390/jcm13237388

Vancouver

Barroso-García N, Martín-Varillas JL, Ferraz-Amaro I, Sánchez-Bilbao L, Martín-Gutiérrez A, Adán A, et al. Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease. Journal of Clinical Medicine. 2024;13(23):7388. doi:10.3390/jcm13237388

BibTeX
@article{BarrosoGarca2024,
  author = {Barroso-García, Nuria and Martín-Varillas, José Luis and Ferraz-Amaro, Iván and Sánchez-Bilbao, Lara and Martín-Gutiérrez, Adrián and Adán, Alfredo and Hernanz-Rodríguez, Inés and Beltrán-Catalán, Emma and Cordero-Coma, Miguel and Díaz-Valle, David and Hernández-Garfella, Marisa and Martínez-Costa, Lucía and Díaz-Llopis, Manuel and Herreras, José M and Maíz-Alonso, Olga and Torre-Salaberri, Ignacio and Atanes-Sandoval, Antonio and Insúa, Santos and Almodóvar-González, Raquel and Fanlo, Patricia and Aberasturi, Juan Ramón De Dios and García-Aparicio, Ángel and Rodríguez-Montero, Sergio and Jovaní, Vega and Moya-Alvarado, Patricia and Peña Sainz-Pardo, Eva and Calvo-Río, Vanesa and Demetrio-Pablo, Rosalía and Hernández, José Luis and Blanco, Ricardo},
  title = {Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {23},
  pages = {7388},
  doi = {10.3390/jcm13237388}
}
Kostenlos starten →